There are currently the following bottlenecks to the manufacturing of biologics, or medications such as gene therapies, vaccines, and etc. that are derived from organic sources such as plants or animals.
The obstacles to large scale biologic dissemination are:
1. Delivering the biologic to the target
2. Manufacturing, producing it at scale
3. Selecting patients for clinical trials in a way that enhances the efficacy of the trial
These challenges have, up until now, made biologics more expensive to administer and that higher price tag can make access limited to the population at large. Significant improvement will come when those bottlenecks release.
Are we on the verge of a breakthrough?
We are pleased to interview Dr. Alexander Koglin, co-founder and CSO of Nature’s Toolbox, in this month’s show who will discuss the progress that is being made in biomanufacturing and what it may mean for society.
The information contained in this website and podcast are purely informational and not considered
investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart
from his role as an investment advisor representative. Nothing contained herein may be construed as a
recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial
affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no
representation that the information conveyed in this material is accurate and is under no obligation to
update this information as changes occur.
